Pharmaceutical Substances - Authors
- Prof. Dr. Axel Kleemann · Frankfurt, GermanyProf. Dr. Axel Kleemann has had a distinguished career in the chemical and pharmaceutical divisions of Degussa AG. From 1987 to 2000, he was a member of the Management Board of ASTA Medica AG with responsibility for Research & Development, Production and Engineering. Axel Kleemann served as Chairman of the Supervisory Board of the German Research Center for Biotechnology, Gesellschaft für Biotechnologische Forschung GBF in Braunschweig from 1993 to 2000. He has been an active Board Member in various organizations and scientific societies, including
- Prof. Dr. Dr. Jürgen Engel · Frankfurt, Germany Prof. Dr. Dr. Jürgen Engel obtained his Ph.D. from the University of Braunschweig in 1975. He joined Degussa in 1976. In 1993 he was appointed head of corporate R&D at ASTA Medica AG, and in the same year received an honorary professorship from TU Dresden. Since 1981 he has also lectured at the University of Regensburg. Since 1990, Jürgen Engel holds the position of an adjunct professor at the School of Pharmacy, University of Regensburg, He was also CEO of Zentaris AG, a spin-off from Asta Medica, from 2003 until 2013 Director of the Board, COO, later President and CEO of Aeterna Zentaris/Quebec City and Managing Director of Aeterna Zentaris GmbH/Frankfurt. He was also engaged as Chairman of the section Medicinal Chemistry of the German Chemical Society, member of the Advisory Committee for the Bio-Center University of Würzburg and Director of the Board of Isotechnika/Edmonton. At present he is member/Chairman of the Advisory Board of Elexopharm GmbH, GIG and Oncoscience AG and board member for the German chemical and pharmaceutical association VCI and BPI for the State of Hesse. In 1995 he received the Galenus von Pergamon Award category B.
- Prof. Dr. Bernhard Kutscher · Weiterstadt, Germany Prof. Dr. Bernhard Kutscher obtained his Ph.D. on peptide synthesis in 1984 from the University of Frankfurt/Main. He joined DEGUSSA in 1984, becoming head of the medicinal chemistry department at ASTA Medica AG in 1987, and later responsibility for the chemical research of the whole corporation. In 2000 he was appointed as the VP R&D of ASTA Medica Oncology. Until Sept. 2012 he was General Manager and VP R&D at Baxter Europe, based in Brussels, and Managing Director of Baxter Oncology GmbH, Halle/Germany. Since 1992 he has also lectured at TU Munich and received an honorary professorship in 1996. Today Bernhard Kutscher is active as a consultant in the field of Drug Development and Manufacturing at BK HC Consulting.
- Dr. Dietmar Reichert · Frankfurt, Germany Dr. Dietmar Reichert studied and completed a Ph.D. in organic chemistry at the Johann Wolfgang Goethe University of Frankfurt/Main on total synthesis of variotin-fungicides in 1992. After postdoctoral research at Cassella AG he joined the chemical department at ASTA Medica AG in 1994 with responsibility for Combinatorial and Automated Syntheses.
In June 2000 he joined Degussa AG at the Hanau-Wolfgang site and was initially working for strategic R&D within the Fine Chemical unit. In 2002 he was appointed Section Manager within the business line "Pharma Intermediates & Exclusive Synthesis". Since 2007 he is responsible for "Strategic projects and Market Intelligence" in Evonik's business line "Exclusive Synthesis & Catalysts".